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Summary
Background While the ingestion of small amounts of an offending food can elicit adverse reactions
in individuals with IgE-mediated food allergies, little information is known regarding these threshold
doses for speciﬁc allergenic foods. While low-dose challenge trials have been conducted on an
appreciable number of allergic individuals, a variety of different clinical protocols were used making
the estimation of the threshold dose very difﬁcult.
Objective A roundtable conference was convened to develop a consensus clinical protocol for lowdose challenge trials for the estimation of threshold doses for speciﬁc allergenic foods.
Methods In May 2002, 20 clinical allergists and other interested parties were invited to participate
in a roundtable conference to develop consensus of the key elements of a clinical protocol for lowdose challenge trials.
Results A consensus protocol was developed. Patients with convincing histories of food allergies and
supporting diagnostic evidence including past challenge trials or high CAP–RAST scores can be
enrolled in low-dose challenge trials. Care must be taken with younger patients to assure that they
have not outgrown their food allergy. An approach was developed for the medication status of
patients entering such trials. Challenge materials must be standardized, for example, partially defatted
peanut ﬂour composed of equal amounts of the three major varieties of peanuts (Florunner, Virginia,
Spanish). Challenge materials must be appropriately blinded with sensory evaluation used to conﬁrm
the adequacy of blinding. A double-blind, placebo-controlled design should be used for low-dose
challenge trials. Low-dose challenge trials would begin at doses of 10 mg of the allergenic food and
would continue with doses of 100 mg and 1 mg followed by speciﬁc higher doses up to 100 mg
depending upon the expert judgement of the physician; even higher doses might be applied to assure
that the patient is indeed reactive to the particular food. A 30-min time interval would be used between
doses, and reactive doses would be expressed as both discrete and cumulative doses. The goal of each
challenge would be to develop objective symptoms; trials should not be discontinued on the basis of
subjective symptoms only. Statistically, a minimum of 29 patients would be enrolled in low-dose
challenge trials for each allergenic food because 0 reactors out of 29 patients at a particular dose allow
the conclusion that there is 95% certainty that 90% of allergic individuals will not react to that dose.
Conclusion A consensus protocol was developed. Using this protocol, it will be possible to estimate
threshold doses for allergenic foods, the lowest amount that elicits mild, objective symptoms in
highly sensitive individuals.
Keywords allergy, clinical trial, DBPCFC, exposure, food, threshold, risk assessment
Submitted 7 July 2003; revised 12 September 2003; accepted 3 November 2003
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Introduction
Allergists know that exposure to small quantities of the
offending food can elicit adverse reactions in individuals with
IgE-mediated food allergies [1, 2]. While the implementation of
strict avoidance diets is prudent clinical advice to give to foodallergic consumers, the assumption of a zero tolerance level for
the offending foods places unachievable burdens on the food
industry for numerous reasons that have been described
previously [3]. Such advice may also unnecessarily restrict the
food choices for patients suffering from food allergies. Thus, in
1999, the Food Allergy Research and Resource Programme at
the University of Nebraska with sponsorship from the worldwide food industry convened a roundtable conference entitled
‘Threshold Doses for Allergenic Foods: How Much is Too
Much?’ The goal of that initial conference was to determine if
data might exist from low-dose, double-blind, placebocontrolled food challenges (DBPCFCs) of individuals with
various IgE-mediated food allergies to allow establishment of
threshold doses for speciﬁc foods.
A threshold dose for allergenic foods is deﬁned for practical
purposes as the lowest observed adverse effect level
(LOAEL), an amount of a speciﬁc food that would elicit
mild, objective symptoms in highly sensitive individuals [3]. In
the determination of the threshold dose, it would also be
desirable to establish the no-observed adverse effect level
(NOAEL), an amount of the speciﬁc food that elicited no
adverse reaction even among individuals with a high degree of
sensitivity to that particular food [3]. The establishment of
threshold doses and NOAELs for speciﬁc allergenic foods
may enable regulatory agencies to establish levels for
allergenic foods that would protect the vast majority of the
sensitive population of consumers. This would provide the
food industry with a target to work toward through good
manufacturing practices and sanitation programmes. Of
course, threshold doses and thus the safe levels of intake
are not likely to be the same for all allergenic foods.
Information from DBPCFCs with low doses of the
offending food demonstrates rather clearly that ﬁnite threshold doses exist below which allergic consumers will not react
[3]. Individuals with IgE-mediated food allergies appear to
vary rather widely in their degree of sensitivity to speciﬁc
allergenic foods, for example, in DBPCFCs with peanutallergic individuals, individual threshold doses ranged from 2
to 450 mg [4, 5]. Sufﬁcient information existed to indicate
that the threshold doses for peanut, egg, and cows’ milk were
in the low milligram range or higher for individuals with
allergies to those speciﬁc foods [3]. However, the establishment of NOAELs or LOAELs for speciﬁc allergenic foods
was not attempted at the 1999 Conference because interpretation of the clinical data was complicated by the use of
different clinical challenge protocols, possible biases in the
selection of patients for low-dose trials, the failure to record
NOAELs during diagnostic challenge trials, and other factors
outlined previously [3].
In 1999, the recommendation was made to undertake an
international effort to develop standardized clinical challenge
protocols for the determination of NOAELs and LOAELs
for various commonly allergenic foods [3]. Thus, in May of
2002, the Food Allergy Research and Resource Programme
at the University of Nebraska again with sponsorship from

the world-wide food industry convened a second roundtable
conference on threshold doses for allergenic foods with the
goal to develop consensus on the elements of a standardized
clinical protocol for low-dose food challenges in highly
allergic patients. This manuscript describes the outcome of
that second conference.

The consensus clinical protocol
Threshold doses can only be determined using DBPCFCs
with low doses of the offending food. Such trials should be
performed in accordance with good clinical practices. Several
elements of the challenge protocol should be standardized so
that data can be compared from multiple clinical investigators. The key elements are outlined in Table 1. DBPCFCs are
already recommended as useful in the diagnosis of food allergies, and many elements of these diagnostic protocols have
already been standardized [6, 7]. However, the lowest doses
used in diagnostic DBPCFCs have not been standardized,
but are instead based upon the nature and severity of the
reaction and the lowest amounts thought to provoke adverse
reactions from the patient’s history [6, 7]. However, typical
starting doses for diagnostic DBPCFCs are in the range of
250–500 mg for the most sensitive patients [8, 9], well above
the levels that are considered in this protocol. However, lower
doses are used on occasion with patients suspected to be
especially sensitive [3].
Considerable discussion is centred around the need for
beneﬁts to accrue to the patients enrolled in such clinical trials
in order to obtain ethics board approvals. Individual patients
would certainly beneﬁt from learning their individual threshold doses, and that knowledge could beneﬁt them in the
implementation of suitable avoidance diets (although they
could conceivably react to a lower dose on some future
occasion). Certainly, a low-dose challenge trial could also be
performed as a component of a normal diagnostic DBPCFC
that would be included in the diagnosis of certain patients
with certain speciﬁc food allergies. A low-dose challenge trial
could also be as part of a DBPCFC that is intended to assess
whether the patient might have outgrown their allergic sensitization. Such challenges are periodically performed especially
on patients where a strong possibility exists that the food
allergy may be outgrown (e.g. cows’ milk, egg, soybean,
wheat) [10]. It may also be possible to couple low-dose
challenge trials to trials of novel therapeutic interventions
where the determination of threshold doses and the alteration

Table 1. Key elements of the consensus clinical protocol
Selection criteria for patients
Natural history of allergic reactions to specific foods
Medical and pharmacological status of patients immediately prior to challenge
Standardization of challenge materials
Challenge vehicles
Blinding of challenge trial
Dosage range for clinical trial
Time interval between doses
Discrete doses vs. cumulative doses
Interpretation of positive responses: objective vs. subjective symptoms
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of the threshold dose in response to the therapy is a necessary
part of the trial design. Even in cases where diagnostic criteria
obviate the need to perform the DBPCFC as part of the
diagnosis, a low-dose challenge trial may be performed to
determine whether certain low or very low doses might be
tolerated by sensitive individuals.

Patient selection criteria
The vast majority of patients with convincing histories and
documented diagnostic evidence of IgE-mediated allergic
reactions to the speciﬁc food can be considered for inclusion
into low-dose DBPCFCs. Patients with histories of severe
anaphylactic reactions may be included in such trials at the
discretion of the physician. Although the possible risks to
such patients are obvious, no proof exists regarding whether
these patients have lower threshold doses than other patients
or not. Obviously, inclusion of such patients in low-dose
challenge trials would yield valuable information in cases
where they are included at the discretion of the physician and
with the consent of the patient or patient’s family. However,
the margin between the threshold dose and the dose that
would provoke a severe reaction is not known either; so
extreme caution should be applied with such patients.
Patients with evidence of allergic sensitization to the speciﬁc
food by history together with skin prick test (SPT) or RAST
could be included in these trials, although ideally patients
enrolled in such trials would have positive DBPCFCs to the
food in consideration. For certain foods, CAP–RAST values
that provide greater than 95% probability that the patient
will experience an allergic reaction to a speciﬁc food have
been established [11, 12]. In some clinics, the CAP–RAST
result obviates the need to perform a DBPCFC at the
standard doses to establish the diagnosis, although low- or
very low-dose challenges may be conducted on such patients
including paediatric cases to determine if they are able to
tolerate such doses and to aid in the development of suitable
avoidance diets. In cases where the CAP–RAST value is
below the established level or for foods where no such CAP–
RAST level has been established, DBPCFCs remain a standard procedure for diagnosis so a low-dose challenge trial
could be incorporated a part of this diagnostic procedure.
Controversy remains regarding CAP–RAST cut-off values
for speciﬁc foods [13]. The inclusion of patients with high
CAP–RAST values but without positive DBPCFCs in lowdose challenge trials is a matter of expert judgement. Ideally,
patients in such trials would have positive DBPCFCs. However, some clinical ethics boards will not allow oral challenges
of patients with high CAP–RAST scores, and it may be
important to include such patients in low-dose challenge
trials.

Natural history of allergic sensitization
As noted, infants and young children often outgrow their
sensitivities to speciﬁc allergenic foods, especially cows’ milk,
eggs, soybeans, and wheat [10]. Obviously, this factor should
be borne in mind when selecting patients for enrollment in
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low-dose challenge trials. With patients where this possibility
exists, the DBPCFC should proceed beyond the low doses to
higher doses that actually provoke adverse reactions where
necessary to assure that a negative response at the lower doses
is truly a negative response and not a false-negative reaction
associated with loss of allergic sensitization. When such
patients have a negative DBPCFC, an open challenge with a
typical amount of the particular food is advocated to conﬁrm
a loss of allergic sensitization [6].

Medical and pharmacological status of patients prior to
challenge
Certain patients should be excluded from low-dose challenge
trials if their allergic conditions are unstable. Examples might
include asthma or chronic urticaria. For asthma, the FEV1
should be 80% of predicted or the patient’s best (whichever is
greater) immediately before the trial commences (in young
children less than 6 years of age, performance of lung
function measurements is not possible so in these cases there
must be no clinical sign of asthma). Inclusion of patients with
highly unstable conditions enhances the likelihood of falsepositive responses. While the exclusion of unstable asthmatics
from such trials is prudent, the assumption is that the
threshold doses for such patients will not be lower than for
other highly sensitive subjects who are enrolled in the trials.
Atopic dermatitis and chronic urticaria should also be well
controlled before enrolling a patient in a low-dose challenge
trial. Other chronic medical conditions may also serve to
exclude certain patients from such trials.
Patients enrolled in low-dose challenge trials should be
taken off all prescribed medications related to their allergies
for suitable withdrawal periods before commencement of the
challenge trial. In particular, H1 antihistamines with a short
duration of activity should be withheld for a minimum of
48 h, hydroxyzine needs to be withheld for a minimum of
72 h, leukotriene receptor antagonists should be withheld
for up to 1 week, and second generation antihistamines
(cetirizine) should be withheld for at least 1 week. In the case
of patients with co-existing or food-induced asthma, shortacting inhaled or oral b-agonists and inhaled anticholinergics
could be continued up to 6 h before challenge. Long-term bagonists should be stopped 12 h before challenge. Chromones
(cromolyn and nedocromil) should be withheld for 48 h.
Inhaled steroids or oral corticosteroids would be continued in
patients where prescribed, although patients with such serious
asthma would probably not be included in low-dose challenge
studies on most occasions. If patients are taken off of routine
medications, the challenge trials must be conducted in a
manner that any reactions arising from the withdrawal of
medications can be distinguished from true reactions to the
food incorporated into the challenge trial. This may require a
challenge day composed entirely of placeboes rather than use
of interspersed placeboes.
No foods should be ingested for 6 h prior to challenge
except in the case of young children where it would be
permitted as necessary. Caffeine and alcohol should also be
excluded for 24 h prior to challenge. While the evidence for
caffeine and alcohol withdrawal is limited, alcohol may in
some cases exacerbate allergic reactions [14] and caffeine is
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known to have pharmacological effects that could conceivably interfere with observations [15].

Standardization of challenge materials
The challenge materials should be standardized for use in
low-dose challenge trials. One of the biggest confounding
variables in existing clinical data on LOAELs is the lack of
uniformity in the selection of challenge materials [3]. For
example with cows’ milk, liquid whole milk, non-fat dry milk,
and infant formula have been used as challenge materials in
various clinics [3]. Challenge materials should be representative of forms of that food that are commonly used by the food
industry and are therefore likely to already have been
identiﬁed as potential allergen risks to the allergic subjects.
However, processing may certainly affect the degree of
allergenicity of speciﬁc foods even though many commonly
allergenic foods are resistant to inactivation during processing
[9]. For threshold studies, the form of the particular food used
as the challenge material should be one that is known to elicit
allergic reactions in most patients with allergies to that
speciﬁc food. The form of the particular food, barring other
considerations, should be one that is particularly well suited
to uniform incorporation into various vehicles. Beyond these
considerations, some arbitrary agreement is needed simply for
the sake of uniformity so that clinical data may be easily
compared from various clinics.
Dry materials tend to be more shelf-stable than liquid
materials. Thus, non-fat dry milk and spray-dried egg white
are advantageous over liquid milk or liquid egg white.
For cows’ milk, non-fat dry milk would be the optimal
choice in terms of consistency and ease of incorporation into
various vehicles. Evidence indicates that processing, including
heating (and presumably drying), has no effect on the
allergenicity of cows’ milk [16].
For egg, spray-dried egg white would be the ideal choice for
similar reasons and because most egg-allergic individuals are
more sensitive to egg white than to egg yolk [17]. Heat processing, including presumably drying, can lessen the allergenicity of egg [18, 19], but most patients do not experience
such differences. Clearly, egg-allergic patients who are sensitive only to raw eggs should be excluded from such trials.
Patients sensitive only to raw eggs have simpler avoidance
diets and little risk from processed foods.
The choice gets more difﬁcult for peanuts because several
different varieties of peanuts are commonly eaten. The group
concluded that the ideal challenge material for peanuts should
be partially defatted peanut ﬂour composed of equal parts of
Florunner, Virginia, and Spanish peanuts; the levels of the
major peanut allergens are similar in all varieties of peanuts
[20]. Because this type of peanut ﬂour is not commercially
available, it would need to be made in a pilot plant facility
using conditions similar to those employed in the commercial
production of commercial peanut ﬂour. Processing, speciﬁcally roasting, enhances the allergenicity of peanuts [21], but
peanut-allergic individuals are known to be allergic to peanut
ﬂour [4]. Obviously, the threshold dose could differ for
roasted peanuts vs. peanut ﬂour but this could be investigated
with this type of DBPCFC approach.

For soybean, partially defatted soy ﬂour was selected as the
optimal challenge material. Although dozens of soybean
varieties are grown commercially, the most common varieties
are intermingled commercially and varietal inﬂuences on
allergenicity are not known to exist. The soybean ﬂour should
be free of genetically modiﬁed soybeans simply to avoid any
possible concern from some ethics boards. Processing may
affect the allergenicity of soybeans, especially fermentation and
preparation of hydrolysates [22, 23]. Soybean ﬂour may be the
most allergenic form of soybean but the comparative allergenicity of various soybean ingredients requires further study.
Both peanut and soybean ﬂours are typically obtained from
heated, rather than raw, seeds and typical commercial
practices should be followed in the preparation of these
challenge materials. Use of specialized pilot plants to prepare
challenge materials (and vehicles) may be necessary in some
situations to prepare varietal mixtures, for example, peanuts
that thus avoid the necessity of conducting multiple trials on
individual varieties, to prevent cross-contamination of raw
materials (e.g. grain mixtures that can occur on farms and in
distribution and storage), and to provide the best characterized challenge material.
Similar considerations should be employed with other commonly allergenic foods in the selection of the most suitable
challenge materials. In some cases such as ﬁsh, the selection
of appropriate challenge materials may be rather difﬁcult
since variations seem to exist in sensitization to speciﬁc ﬁsh
species [24].

Challenge vehicles and blinding of challenges
The challenge materials should be incorporated into challenge
vehicles in a centralized locale and distributed to various
clinics participating in the low-dose challenge trial. This
approach would maximize consistency and provide the easiest
interpretation of the resulting data.
The challenge vehicles should be shelf-stable; refrigeration
or freezing causes logistical problems in distribution from a
centralized location. Capsules were not recommended because they are difﬁcult to administer to younger patients and
they often dissolve slowly in the gastrointestinal tract. Lowfat vehicles should be used since fat slows digestion of protein. The challenge material should be simple to incorporate
into the challenge vehicle. An example would be the use of an
intensely ﬂavoured gelatin dessert where deﬁned doses of the
challenge material might be incorporated into individual
small containers. The only steps at the clinic would then be
the addition of a deﬁned amount of water, mixing, and
refrigeration to allow gelation. Of course, use of gelatin can
raise concerns due to religious restrictions and dietary/cultural
preferences since it is often derived from pork. Instant
oatmeal, instant mashed potatoes, and instant pudding are
other possible challenge vehicles that eliminate this concern.
Care must be taken to exclude patients with allergies to components of the challenge vehicle, for example, milk in instant
pudding.
The challenges should be appropriately blinded. Sensory
evaluation should be used with individuals not included in the
challenge trial to assure that the challenge material cannot be
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detected in the vehicle at the highest dose. A simple triangle
test can be used in sensory evaluation for such purposes [25].
The addition of ﬂavours is important to the ability to mask
any ﬂavour associated with the challenge material. Care must
be taken to select ﬂavouring materials that do not contain
any materials derived from commonly allergenic foods.
Flavouring components can occasionally be derived from
known allergenic sources [26].

Dosage range for the challenge trials
For low-dose challenge trials, a double-blind and placebocontrolled design should be employed. Placeboes should be
the challenge vehicle alone. Placeboes can be interspersed
randomly on a single day where necessary to obtain the
patient’s consent, but the preferred approach is use of a
separate placebo day. As noted previously, a separate placebo
day is advisable in situations where the patient has been
withdrawn from key medications known to be necessary to
control their chronic condition (asthma, urticaria, atopic
dermatitis).
Consensus was achieved on an ideal dosage range and
challenge protocol to use in these low-dose challenge trials.
The consensus was based primarily upon experience obtained
with peanuts, cows’ milk, and eggs. The dosage range might
need to be modiﬁed for other allergenic foods based upon
expert considerations.
For patients enrolled in these trials on the basis of history,
SPT, or CAP–RAST below the 95% probability value as
described in patient selection criteria, the low-dose challenge
trial would be incorporated into a normal diagnostic
DBPCFC. Doses of 10 mg, 100 mg, and 1 mg of the allergenic
food would be followed by higher doses up to 100 mg
depending upon the expert judgement of the physician. A
separate placebo day would be used. The order of administration of placebo (ﬁrst or second trial day) would be random
and blinded. A dose of 10 mg has never been associated with
elicitation of subjective or objective symptoms in any
previous low-dose challenge trials so the selection of this
dose should be safe even for highly sensitive patients. The
inclusion of the 10 mg dose also helps to assure that a NOAEL
will be determined. The 100 mg dose has been implicated in
mild, transient, subjective symptoms in one low-dose
challenge trial with peanuts [4]. The lowest dose of an
allergenic food provoking an objective reaction was 1 mg for
peanuts and eggs [3]. If the low-dose challenge is used as a
part of a normal diagnostic protocol or as a part of a protocol
to determine if a speciﬁc allergy has been outgrown, even
much higher doses may need to be included to provoke an
adverse reaction in most allergic patients.
For patients selected on the basis of a CAP–RAST score
that is 495% predictive of an allergic reaction, the low-dose
challenge trial would be designed to determine doses that the
individual patient could tolerate. In this case, the entire trial
with randomly interspersed placeboes could be conducted on
a single day, but use of a separate placebo day remains the
preferred approach. Doses of 10 mg, 100 mg, 500 mg, and 1 mg
of the allergenic food would be used. Based on past
experiences with low-dose challenges, a 1 mg dose would be
expected to elicit a mild, objective adverse reaction in no more
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than 5% of the sensitive patients. This 1 mg dose would be
equivalent to 20 p.p.m. in a food with a 50-g serving size.

Time interval between doses
The time interval between discrete doses in the low-dose
challenge trial should be 30 min. As noted earlier, a 30-min
interval does not provide sufﬁcient time for complete
assimilation of the challenge material but longer intervals
would simply be impractical. With the results presented on
the basis of both the cumulative and the discrete doses, any
concerns about the selection of the time interval should be
abated. The physician could delay the administration of the
succeeding dose at their discretion if the situation warranted,
for example, the patient complains of subjective symptoms
but no objective signs are visible. Provision should also be
made for administration of an identical or placebo dose
before proceeding to the next higher dose if such a decision is
considered prudent by the physician for reasons similar to
those noted above.

Discrete vs. cumulative doses
When positive responses are obtained in low-dose DBPCFCs,
the results should be recorded in terms of the discrete dose
(the dose administered just prior to the onset of the positive
response) and the cumulative dose (the sum of all doses given
prior to the onset of the positive response). Using reasonable
time intervals including the recommended 30-min intervals,
the digestion of discrete doses of the allergenic food and the
allergenic proteins contained therein is probably incomplete
before administration of the next discrete dose. Therefore, the
expression of the results as a cumulative dose is probably
justiﬁed since a clear break does not occur between individual
doses. However, the reporting of both the discrete dose and
the cumulative dose is relatively easy and provides the
maximum information of later use and interpretation.

Subjective vs. objective responses
The assessment of patients’ responses to the low-dose
challenge is clearly a matter of expert clinical judgement. In
all cases, the reasons for stopping the challenge sequence
should be carefully and thoroughly recorded. Completely
subjective symptoms (e.g. mouth itching) should not serve as
the basis for cessation of the challenge trial but could serve as
a reason to repeat a speciﬁc dose in the challenge sequence.
Subjective symptoms are potentially meaningful in circumstances where such symptoms are not encountered during the
placebo challenge (not known until trial is completed), so
subjective reactions should be carefully recorded. However,
the progression of the challenge trial to one or more higher
doses that elicit an objective symptom is needed before
cessation of the trial. Standardized scoring systems should be
developed and employed to document any objective symptoms. Observations should be recorded in a uniform manner.
For mild objective symptoms (e.g. one or two small urticarial
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lesions that spontaneously resolve), experts might disagree
regarding whether the response was a positive response to the
challenge. In such situations, a small group of four to ﬁve
expert allergists should be consulted for their opinions. In
these circumstances, photographs should be taken of these
symptoms and shared. Again, the development of very mild,
objective symptoms could serve as the basis to repeat a
speciﬁc dose in the challenge sequence.
Many allergic patients have somewhat unpredictable manifestations and normal variability likely exists with respect to
mild responses to low-dose challenges. Because reactions at
the lowest doses would have profound implications in the
identiﬁcation of LOAELs and NOAELs, the reproducibility
of these responses should be sought in certain situations. If
mild, objective reactions occur at the very lowest doses in the
protocol (either the 10 mg or 100 mg doses), these responses
would be considered especially unusual. In these circumstances, a repeat of the entire low-dose challenge trial should
be performed on a different day. If possible, this rechallenge
should occur within 7 days with a maximum time interval
between challenges of 6 weeks. The minimum time interval
between challenges would be 24 h, although a repeat challenge
might be possible on the same day if the symptoms resolve
spontaneously. If the patient reacts again to the lowest challenge dose (10 mg) with objective symptoms, then a NOAEL
has clearly not been established; another challenge of this
patient with an even lower dose of 1 or 5 mg would be
desirable in such circumstances.
The interpretation of patient responses to low-dose challenges is an extremely important element of the protocol. The
progression of the challenge trial to a point where mild,
objective symptoms are encountered serves to remove some
potential controversy. Risk assessments should ideally be
based on the lowest doses eliciting objective symptoms rather
than upon lower doses eliciting subjective symptoms. Even in
circumstances where a patient experiences subjective symptoms at a low dose that are conﬁrmed by objective symptoms
at higher doses, the risk assessment should be based upon the
doses eliciting objective symptoms. In low-dose challenge
trials with peanuts, subjective symptoms were encountered in
some patients at doses (100 mg) that were 20-fold lower than
the lowest doses provoking mild objective reactions [4]. As
noted previously, the threshold dose is deﬁned as the LOAEL
that elicits mild, objective symptoms in highly sensitive
individuals [3]. In cases where repeat challenges are
performed that yield differing results at the same low doses
on separate occasions, the positive result cannot be discounted in the risk assessment. However, the variability in the
response could be taken into account.

Statistical interpretation and risk assessment
The goal to be achieved from standardized and comparable
low-dose challenges of sensitive patients would be the
establishment of threshold levels that would protect the vast
majority of allergic consumers. A typical approach would be
to conduct low-dose challenges using this standardized
protocol on a total of 29 patients with a speciﬁc food allergy.
If a level can be identiﬁed that does not elicit an adverse
reaction in any of the 29 subjects, then statistically it can be

concluded that 95% certainty exists that 90% of allergic
individuals will not react to this dose of the particular
allergen. While this level of assurance clearly does not protect
all patients, this approach has been advocated in the
development of hypoallergenic infant formula [27]. While
hypoallergenic infant formula is safe for the vast majority of
cows’ milk-allergic infants, occasional allergic reactions are
noted in exquisitely allergic infants [28–32]. The only method
to determine if a particular threshold dose would protect a
speciﬁc patient would be to conduct a low-dose DBPCFC.
Alternatively, existing clinical data from low-dose challenges from multiple clinics using somewhat different protocols could be assessed statistically. This approach was
recently tried by Bindslev-Jensen et al. [33] using published
data from the clinical literature. However, this approach is
complicated by the uncertainties associated with failure to
identify a NOAEL in most existing observations, the effects
of differences in the protocols, and other factors [33]. Using
this approach, threshold values that would protect 99 of 100
allergic individuals were 8.6 mg (milk), 3.4 mg (egg), 1.2 mg
(peanut), and 2.2 mg (soybean) [33]. The reliability of these
estimates would improve with data from standardized clinical
protocols.
Additionally, the risk assessment will likely need to include
expert clinical and regulatory judgement beyond simple statistical interpretations. Other factors such as the seriousness
of the reaction, objective vs. subjective reactions, and the
inclusion of uncertainty factors to account for the possible
existence of more highly sensitive individuals will also need to
be considered. Also, the expression of the threshold dose will
need to include an acceptable degree of risk. Bindslev-Jensen
et al. [33] estimated threshold doses for degrees of risk
ranging from one in a million to one in a hundred. No
international agreement has been reached on an acceptable
level of risk for allergic individuals. Thus, further discussion
regarding the application of risk assessment principles to
actual data from low-dose challenges will be anticipated once
data become available from the standardized clinical protocol
outlined here.
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